- Home
- REFR vs LVTX Comparison
REFR vs LVTX Comparison
Compare REFR & LVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REFR
- LVTX
- Stock Information
- Founded
- REFR 1965
- LVTX 2016
- Country
- REFR United States
- LVTX Netherlands
- Employees
- REFR N/A
- LVTX N/A
- Industry
- REFR Multi-Sector Companies
- LVTX Biotechnology: Pharmaceutical Preparations
- Sector
- REFR Miscellaneous
- LVTX Health Care
- Exchange
- REFR Nasdaq
- LVTX Nasdaq
- Market Cap
- REFR 49.5M
- LVTX 41.3M
- IPO Year
- REFR N/A
- LVTX 2021
- Fundamental
- Price
- REFR $1.25
- LVTX $1.54
- Analyst Decision
- REFR
- LVTX Hold
- Analyst Count
- REFR 0
- LVTX 4
- Target Price
- REFR N/A
- LVTX $1.58
- AVG Volume (30 Days)
- REFR 25.8K
- LVTX 111.6K
- Earning Date
- REFR 11-06-2025
- LVTX 08-13-2025
- Dividend Yield
- REFR N/A
- LVTX N/A
- EPS Growth
- REFR N/A
- LVTX N/A
- EPS
- REFR N/A
- LVTX N/A
- Revenue
- REFR $1,222,239.00
- LVTX $4,990,000.00
- Revenue This Year
- REFR N/A
- LVTX N/A
- Revenue Next Year
- REFR N/A
- LVTX N/A
- P/E Ratio
- REFR N/A
- LVTX N/A
- Revenue Growth
- REFR N/A
- LVTX N/A
- 52 Week Low
- REFR $0.93
- LVTX $0.85
- 52 Week High
- REFR $2.35
- LVTX $2.09
- Technical
- Relative Strength Index (RSI)
- REFR 32.31
- LVTX 52.34
- Support Level
- REFR $1.24
- LVTX $1.53
- Resistance Level
- REFR $1.33
- LVTX $1.58
- Average True Range (ATR)
- REFR 0.06
- LVTX 0.04
- MACD
- REFR -0.00
- LVTX -0.01
- Stochastic Oscillator
- REFR 12.00
- LVTX 44.94
About REFR Research Frontiers Incorporated
Research Frontiers Inc is engaged in the development and marketing of technology and devices to control the flow of light. The company develops and licenses its patented suspended particle device light-control technology to other companies that manufacture and market the SPD-Smart chemical emulsion, the light-control film made from the chemical emulsion, the light-control panels made by laminating the film, electronics to power end-products incorporating the film, or lamination services for, and the end-products. The company's revenue source comes from the licensing of technology.
About LVTX LAVA Therapeutics N.V.
LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.